Survodutide cut body weight 13% versus 5.4% on placebo in phase 3

What is survodutide?

Survodutide (BI 456906) is a once-weekly injectable peptide that activates both the glucagon receptor (GCGR) and the GLP-1 receptor. Chemically, survodutide is a 29-residue acylated peptide, dosed by subcutaneous injection.

GLP-1 receptor agonism is the mechanism semaglutide and tirzepatide already exploit: it slows gastric emptying, increases satiety signaling, and reduces food intake.

The glucagon receptor is the added variable. Glucagon receptor activation increases hepatic glucose output and, in preclinical models, drives measurable increases in energy expenditure, something GLP-1 alone does not do. That second receptor makes survodutide mechanistically distinct from single-target GLP-1 drugs.

How much weight do people lose on survodutide?

Adults with obesity on survodutide 6.0 mg lost a mean 13.0% of body weight over 76 weeks in the phase 3 SYNCHRONIZE-1 trial, versus 5.4% on placebo ^[4].

That 13.0% figure uses the treatment-regimen estimand, the more conservative, intention-to-treat-style analysis. Under the efficacy estimand, which counts participants who stayed on treatment as assigned, mean loss reached up to 16.6% ^[4]. SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were published in mid-2026.

SYNCHRONIZE-1 built on a phase 2 dose-finding RCT in adults with obesity without diabetes. In that trial, once-weekly survodutide at 4.8 mg produced a mean 14.9% body-weight reduction at 46 weeks, versus 2.8% with placebo, with a clear dose-response relationship across the active arms ^[2].

Does survodutide reduce liver fat and MASH?

Survodutide beat placebo on liver outcomes in two trials: a phase 2 MASH trial ^[3] and the phase 3 SYNCHRONIZE-MASLD trial ^[5].

The phase 2 RCT enrolled adults with biopsy-confirmed MASH and stage F1 to F3 fibrosis. At 48 weeks, up to 62% of survodutide-treated participants showed histologic improvement without worsening of fibrosis, versus 14% on placebo ^[3].

SYNCHRONIZE-MASLD was a 48-week phase 3 trial in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). By MRI-PDFF, 84.2% of survodutide-treated participants achieved at least a 30% reduction in liver fat content, versus 24.3% on placebo. Mean body weight fell 12.2%, versus 1.0% on placebo ^[5].

Is survodutide better than semaglutide or tirzepatide?

No human trial cited below compared survodutide head-to-head with semaglutide or tirzepatide. Survodutide's 13.0% phase 3 weight loss ^[4] is competitive with other GLP-1-based drugs, not proven superior.

The only cited direct comparison with semaglutide comes from mice. In mice, BI 456906 produced greater body-weight reduction than maximally effective doses of semaglutide, an effect attributed to appetite suppression combined with increased energy expenditure, not appetite suppression alone ^[1].

Energy-expenditure effects that look robust in mice do not automatically scale to the same magnitude, or the same safety profile, in humans. The phase 2 and phase 3 human trials were not designed to isolate how much of the weight loss comes from energy expenditure versus appetite suppression.

For the comparators' own evidence, see semaglutide's randomized trial record and what the tirzepatide trials show.

Is survodutide approved?

No regulatory body has approved survodutide anywhere, although its weight-loss evidence earns grade B (good) from two published phase 2 RCTs and two published phase 3 RCTs.

Grade B reflects multiple RCTs, dose-dependent effects, and phase 3 confirmation at the registrational level. Survodutide's human evidence is better documented than most compounds circulating in research-peptide communities. "Phase 3 published in NEJM and Nature Medicine" is a stronger evidence claim than "phase 2 topline numbers," the distinction most forum coverage skips.

Grade B is still not a breakthrough. Every trial published so far is industry-sponsored, run by the company developing the molecule, and no independent, non-sponsor replication exists in the public record. The phase 3 cardiovascular outcomes trial, SYNCHRONIZE-CVOT (NCT06077864), has not reported. Published phase 3 data are not the same as an approved drug with years of post-market surveillance.

What side effects does survodutide cause?

Dose-dependent nausea, vomiting, and diarrhea are survodutide's main side effects and the primary reason people discontinue. Reduced appetite, early satiety, injection-site reactions, and a possible heart-rate elevation also appear across the program.

The glucagon receptor, the feature that makes survodutide distinct from semaglutide, introduces risks semaglutide users do not face in the same way. Glucagon receptor agonism increases hepatic glucose output, the opposite of what someone chasing metabolic health typically wants a weight-loss compound doing to their blood sugar. The dual-agonist class also carries a heart-rate increase signal, consistent with glucagon's known cardiac effects.

None of this means survodutide is unsafe at the doses and durations studied so far. It means "dual agonist" is not shorthand for "more of a good thing." Survodutide has a different risk profile, not a strictly better one, and the trials to date were not designed or powered to compare that profile head-to-head against an approved single-target GLP-1 drug.

Is there a safe survodutide dosing schedule?

No validated self-administration schedule for survodutide exists. The published results came from monitored clinical trial schedules, and the full step-by-step titration protocol has not been published in a form that translates into a self-administration schedule.

Semaglutide and tirzepatide schedules do not transfer. The pharmacokinetics of a GCGR/GLP-1R dual agonist are not interchangeable with those of semaglutide or tirzepatide, which have different receptor affinities, half-lives, and dose-response curves. A titration schedule borrowed from another peptide's package insert is a guess dressed up as a protocol.

The gap is not forum laziness. The underlying dosing data have not been made public in a usable form, and with survodutide unapproved, they may never be.

Is research-grade survodutide the same as the trial drug?

Research-grade survodutide is not the trial drug: survodutide has no approved formulation, so anything sold outside a clinical trial is unregulated research material.

Those vials carry no chain-of-custody guarantee on purity or even correct identity, and the trial results do not validate an independently supplied research formulation. The sourcing risk applies equally to every unapproved research peptide. Impressive phase 3 numbers do not change what is in an unverified vial.

What is still unknown about survodutide?

Survodutide's open questions center on cardiovascular safety, independent replication, and safety beyond roughly 76 weeks:

• Cardiovascular outcomes. SYNCHRONIZE-CVOT is still pending, and its result matters directly given the heart-rate signal already observed.
• Independent replication. No independent lab outside the sponsor's trial network has replicated the phase 3 findings.
• Long-term safety. Survodutide's safety beyond roughly 76 weeks has not been studied.
• Source of the weight loss. The human trials were not designed to separate the energy-expenditure share of the weight loss from the appetite-suppression share.